Showing results (251-260 of 287) with videos related to

Sort By:
Pageof 29
Journal of Virology|February 1, 1997
Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognitionC C Wilson, S A Kalams, B M Wilkes, et al.
Nature|June 1, 2026
Passive heart-rate monitoring during smartphone use in everyday lifeShun Liao, Paolo Di Achille, Jiang Wu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2013
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialPatrick Vermersch, Anna Czlonkowska, Luigi M E Grimaldi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2022
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension studyCorey C Ford, Jeffrey A Cohen, Andrew D Goodman, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 23, 2022
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple SclerosisEleni S Vasileiou, Chen Hu, Charles N Bernstein, et al.
Neurology|April 1, 1998
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.
Neurology|July 22, 2020
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extensionStephen L Hauser, Ludwig Kappos, Douglas L Arnold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 16, 2025
Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMSDouglas L Arnold, Shannon Kolind, Haz-Edine Assemlal, et al.
CNS Drugs|January 19, 2020
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 StudyRobert T Naismith, Annette Wundes, Tjalf Ziemssen, et al.
Annals of Neurology|April 18, 1998
Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosisM Filippi, M A Horsfield, H J Adèr, et al.
Pageof 29